298 related articles for article (PubMed ID: 25858855)
1. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
[TBL] [Abstract][Full Text] [Related]
2. CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice.
Malanchère-Brès E; Payette PJ; Mancini M; Tiollais P; Davis HL; Michel ML
J Virol; 2001 Jul; 75(14):6482-91. PubMed ID: 11413315
[TBL] [Abstract][Full Text] [Related]
3. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
Wild J; Grusby MJ; Schirmbeck R; Reimann J
J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
[TBL] [Abstract][Full Text] [Related]
4. [Humoral and cellular immunogenecity of genetic vaccine on core gene of hepatitis B virus in mice].
Huang Z; Lu S; Liu N
Zhonghua Yi Xue Za Zhi; 1999 Jun; 79(6):456-9. PubMed ID: 11715443
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma.
Böcher WO; Herzog-Hauff S; Schlaak J; Meyer zum Büschenfeld KH; Löhr HF
Hepatology; 1999 Jan; 29(1):238-44. PubMed ID: 9862872
[TBL] [Abstract][Full Text] [Related]
6. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen.
Hsu HY; Chang MH; Hsieh RP; Ni YH; Chi WK
Hepatology; 1996 Dec; 24(6):1355-60. PubMed ID: 8938161
[TBL] [Abstract][Full Text] [Related]
7. Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse.
Böcher WO; Galun E; Marcus H; Daudi N; Terkieltaub D; Shouval D; Löhr HF; Reisner Y
Hepatology; 2000 Feb; 31(2):480-7. PubMed ID: 10655274
[TBL] [Abstract][Full Text] [Related]
8. Induction of oral tolerance towards hepatitis B envelope antigens in a murine model.
Gotsman I; Beinart R; Alper R; Rabbani E; Engelhardt D; Ilan Y
Antiviral Res; 2000 Oct; 48(1):17-26. PubMed ID: 11080537
[TBL] [Abstract][Full Text] [Related]
9. Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice.
Oka Y; Akbar SM; Horiike N; Joko K; Onji M
Immunology; 2001 May; 103(1):90-7. PubMed ID: 11380696
[TBL] [Abstract][Full Text] [Related]
10. Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection.
Milich DR
J Viral Hepat; 1997; 4 Suppl 2():48-59. PubMed ID: 9429210
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice.
Shimizu Y; Guidotti LG; Fowler P; Chisari FV
J Immunol; 1998 Nov; 161(9):4520-9. PubMed ID: 9794377
[TBL] [Abstract][Full Text] [Related]
12. Ongoing murine T1 or T2 immune responses to the hepatitis B surface antigen are excluded from the liver that expresses transgene-encoded hepatitis B surface antigen.
Schirmbeck R; Wild J; Stober D; Blum HE; Chisari FV; Geissler M; Reimann J
J Immunol; 2000 Apr; 164(8):4235-43. PubMed ID: 10754320
[TBL] [Abstract][Full Text] [Related]
13. Characterization of T-cell tolerance to hepatitis B virus (HBV) antigen in transgenic mice.
Takashima H; Araki K; Miyazaki J; Yamamura K; Kimoto M
Immunology; 1992 Mar; 75(3):398-405. PubMed ID: 1533387
[TBL] [Abstract][Full Text] [Related]
14. Antigen-antibody complex as therapeutic vaccine for viral hepatitis B.
Wen YM; Qu D; Zhou SH
Int Rev Immunol; 1999; 18(3):251-8. PubMed ID: 10614727
[TBL] [Abstract][Full Text] [Related]
15. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.
Weeratna RD; Brazolot Millan CL; McCluskie MJ; Davis HL
FEMS Immunol Med Microbiol; 2001 Dec; 32(1):65-71. PubMed ID: 11750224
[TBL] [Abstract][Full Text] [Related]
16. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype.
Milich DR; Schödel F; Hughes JL; Jones JE; Peterson DL
J Virol; 1997 Mar; 71(3):2192-201. PubMed ID: 9032353
[TBL] [Abstract][Full Text] [Related]
17. Polyvalent vaccination against hepatitis B surface and core antigen using a dicistronic expression plasmid.
Wild J; Grüner B; Metzger K; Kuhröber A; Pudollek HP; Hauser H; Schirmbeck R; Reimann J
Vaccine; 1998 Feb; 16(4):353-60. PubMed ID: 9607055
[TBL] [Abstract][Full Text] [Related]
18. Characterization of humoral and CD4+ cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens.
Sällberg M; Townsend K; Chen M; O'Dea J; Banks T; Jolly DJ; Chang SM; Lee WT; Milich DR
J Virol; 1997 Jul; 71(7):5295-303. PubMed ID: 9188598
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice.
Zheng BJ; Ng MH; He LF; Yao X; Chan KW; Yuen KY; Wen YM
Vaccine; 2001 Jul; 19(30):4219-25. PubMed ID: 11457548
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells.
Akbar SM; Abe M; Masumoto T; Horiike N; Onji M
J Hepatol; 1999 May; 30(5):755-64. PubMed ID: 10365798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
